Schwannoma clinical trials at UC Cancer
2 research studies open to eligible people
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2
open to eligible people ages 12 years and up
This is a multi-arm phase II platform-basket screening study designed to test multiple experimental therapies simultaneously in patients with neurofibromatosis type 2 (NF2) with associated progressive tumors of vestibular schwannomas (VS), non-vestibular schwannomas (non-VS), meningiomas, and ependymomas. This Master Study is being conducted as a "basket" study that may allow people with multiple tumor types associated with NF2 to receive new drugs throughout this study. Embedded within the Master Study are individual drug substudies. - Investigational Drug Sub-study A: Brigatinib
at UCLA
Intraoperative Electrically-evoked ABRs in Patients Undergoing Vestibular Schwannoma Surgery
open to eligible people ages 18-99
This is a study of the feasibility of activating the auditory system by an electrode in direct contact with the cochlear nerve.
at UC Irvine
Our lead scientists for Schwannoma medical studies include John C Middlebrooks, PhD Harrison M Lin, MD.
Last updated: